The Actinic Keratosis Treatment Market is experiencing a surge in growth, driven by rising public awareness of the condition and the emergence of innovative treatment options. A recent market analysis forecasts a robust Compound Annual Growth Rate (CAGR) of 7.2% from 2024 to 2034. This translates to a projected market valuation exceeding US$12.28 billion by 2034, reflecting a near-doubling from its US$6,128.2 million value in 2024.
The growth of the Global Actinic Keratosis Treatment Industry is primarily attributed to factors such as the increasing prevalence of actinic keratosis, rising demand for actinic keratosis treatment products, a promising pipeline of potential drugs, and a preference for topical treatments. Additionally, the market is being driven forward by the rising incidence of skin cancer and the growing demand for minimally invasive procedures.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-3233
Who Is Winning?
The Global Actinic Keratosis Treatment Industry report tracks the key market players, which include GlaxoSmithKline Plc. Nestle SA, Novartis AG, Sun Pharmaceutical Ltd., Leo Pharma Inc., etc. Leading manufacturers in the Global Actinic Keratosis Treatment Industry are focusing on acquisitions to enhance their product portfolio. For instance, in November 2015, Leo Pharma A/S completed the acquisition of the dermatology business of Astellas Pharma. With this acquisition, the company expanded its dermatology product portfolio segment. Companies are also focusing on segment leadership. In February 2016, Cipher Pharmaceuticals Inc. launched Actikerall for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis to mark their leadership in the topical product segment.
Combination therapies such as topical fluorouracil cryotherapy, PDT and imiquimod therapy, chemical peels, and 5-FU are generally the most prescribed therapies for actinic keratosis. Convenient administration, lower potential for irritation, and systemic absorption continue to underpin their high adoption rate. The development of drugs with increased efficacy and decreased side effects that can be used as combination therapy for actinic keratosis treatment is currently the focal point of global market leaders. Biofrontera AG commercially launched its product Ameluz (2016), used in combination with PDT for actinic keratosis treatment.
Development of minimally invasive drug-device combination therapies and fast-track regulatory approval for pipeline drugs will be offering a completely new set of treatment options for actinic keratosis shortly.
Key Takeaways – Actinic Keratosis Treatment Market Study
- The growing use of topical products as the first-line preference for actinic keratosis treatment is offering huge opportunities to market players to develop and launch new topical products for actinic keratosis treatment.
- Increasing collaboration activities by key market players of the actinic keratosis treatment market with other companies to broaden their product portfolio is anticipated to propel the actinic keratosis treatment market growth.
- For instance, in March 2017, Galderma SA (Nestle Skin Health Company) collaborated with Colorescience, to enhance its product portfolio for aesthetic treatment.
- Increasing product approvals of actinic keratosis treatment by regulatory bodies is expected to fuel the actinic keratosis treatment industry growth.
- For instance, in March 2018, the combination of Ameluz and daylight photodynamic therapy (PDT) by Biofrontera AG got approval from the European Union.
- The U.S. and Australia’s marked rise in the incidence and prevalence of actinic keratosis will remain highly prominent markets for actinic keratosis treatment providers.
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the actinic keratosis treatment industry in its latest study, presenting historical demand assessment from 2014 to 2018 and projections from 2022 to 2028 based on treatment categories (topical treatment, procedural modality, photodynamic therapy and others), disease type (clinical AK and subclinical AK)and end-user (hospitals, laser therapy centers, private dermatology clinics, spas and rejuvenation centers, cancer treatment centers, homecare) in seven key regions.
Level Up Your Market Understanding – Purchase Now!
https://www.futuremarketinsights.com/checkout/3233
Actinic Keratosis Treatment Market By Category
By Treatment Type:
- Topical Treatment
- 5-fluorouracil Cream
- Diclofenac Gel
- Imiquimod Cream
- Ingenol mebutate Gel
- Procedural Modality
- Chemical Peels
- Cryotherapy
- Photodynamic Therapy
- Others
By Disease Type:
- Clinical AK
- Subclinical AK
By End User:
- Hospitals
- Private Dermatology Clinics
- Laser Therapy Centers
- Cancer Treatment Centers
- Spas and Rejuvenation Centers
- Homecare
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
